Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Short term Debt (2020 - 2023)

Mirum Pharmaceuticals has reported Short term Debt over the past 4 years, most recently at $1.1 million for Q1 2023.

  • Quarterly results put Short term Debt at $1.1 million for Q1 2023, down 45.39% from a year ago — trailing twelve months through Mar 2023 was $1.1 million (down 45.39% YoY), and the annual figure for FY2022 was $1.1 million, down 45.39%.
  • Short term Debt for Q1 2023 was $1.1 million at Mirum Pharmaceuticals, roughly flat from $1.1 million in the prior quarter.
  • Over the last five years, Short term Debt for MIRM hit a ceiling of $2.2 million in Q2 2021 and a floor of $847000.0 in Q3 2021.
  • Median Short term Debt over the past 4 years was $1.5 million (2020), compared with a mean of $1.5 million.
  • Peak annual rise in Short term Debt hit 114.62% in 2022, while the deepest fall reached 45.39% in 2022.
  • Mirum Pharmaceuticals' Short term Debt stood at $1.3 million in 2020, then soared by 57.91% to $2.0 million in 2021, then tumbled by 45.39% to $1.1 million in 2022, then changed by 0.0% to $1.1 million in 2023.
  • The last three reported values for Short term Debt were $1.1 million (Q1 2023), $1.1 million (Q4 2022), and $1.8 million (Q3 2022) per Business Quant data.